Member Info for jint

Datamajik carried out the Sprinter data analysis, not sure if they are carrying out the ‘deep dive analysis’.

http://datamagik.co.uk/

Hi Manifesto,
Information from a poster on another board may answer your query:
Polar Capital LLP is a limited liability partnership registered in England and Wales with registration number OC314700.

Ndn71,
Your forgetting that if someone was to infringe a patent pending, once granted they would be liable for all losses back to the original priority filing date plus damages, not many would risk that with a well crafted patent application as Synairgen’s.

@Pharma123
It has not been granted it’s gone through as an application via a PCT application which allows the applicant Synairgen to apply for patent protection. The Patent Cooperation Treaty (PCT) assists applicants in seeking patent protection internationally for their inventions in member countries.

The application has still to go through the normal procedures by the patent examiners, searches for prior art etc etc, the whole process for grant could take between 2-4years maybe longer, remember they are applying for in effect a monopoly of 20years plus a possible additional 5years under the SPC (supplementary protection certificate) provision, for pharmaceutical products an allowance made for the time it takes to pass regulatory requirements.

The point to remember is the Priority filing date back in July 2020, that’s the protection Synairgen have for any latecomers to the scene.

This link may help as to the procedures:
https://www.uspto.gov/web/offices/pac/mpep/s1842.html

Hi Manifesto, like wise, it’s been a long journey that’s soon to come to fruition, the PCT patent application content is excellent.

@Docdaneeka
If they look carefully through the documents section of the Patent application it clearly states that those named in certain areas are not necessarily the inventors.

@manifesto your question was a valid one, hopefully I’ve answered it for you, great to have you back posting again by the way!

Of course the Sprinter trial is the main focus for Synairgen as opposed to the ACTIV2 initiative which is not under their control although supported via drug supply.

However, it does speak volumes that Synairgen have put in place the necessary manufacturing capacity within the US, so yes it is a the prime target and probably the most important.

Lastly the quip regarding ‘obsession’ was unnecessary and far from the reality.

From publication the normal process for all patents applications will take place.

Post publication this process between the Patent office examiners and Synairgen‘s patent attorneys will take time for novelty to be confirmed before the patent is granted.

It’s certainly not a five minute job, remember a patent gives the holder a monopoly for the term of the patent in the territories that it has been granted in.

Alhambra - the new patent applications are going through normal due process, nothing to be concerned about.

Two of the first of Synairgen’s patents applications (Covid related) are not due to be published until Jan/Feb 22.
A further application(COPD related) publication due March/April 22.
The last one filed (Covid related) is due for publication Oct/Nov 22.

We will not receive any further updates on these applications until publication and there contents are in the public domain.

It would seem reasonable that devices (even those approved) would need approval when being used with a new substance (therapeutic).

Assurance would be required to ensure no degradation of device materials ensues following use of a new substance (therapeutic).

small trader -
SGN018 is Synairgen’s own financed Phase3 trial for hospitalised patients.

ACTIV2 Phase2/3 trial is treating Covid confirmed patients at home and is financed by the U.S.

We are currently waiting on news re: ACTIV2 as to whether SGN001 is going to progress to Phase3.
It looks promising, SGN001 being one of three currently under review, if successful the Phase3 part of this will begin in October.

wpa5 - I do remember RM stating there could possibly be interim results issued however, I seem to remember that statement being in the context of unexpected delays in the trial finishing within the expected timescales.

Due to the trial appearing to be nearing completion, I do not envisage a statement on interim results to be issued.

@JJess - thumbs up :)

and we know we have the best formulation.

@mact4…..ambitious maybe, buts that my target before I even look at giving up any of these once in an investing lifetime golden tickets.

When the time comes we will know that our outstanding BoD will have carried out their best endeavours to maximise shareholders return . I believe they are one of the best management teams on the AIM.

Yes, fingers crossed for our Phase3, my confidence is high with endless science papers supporting interferon treatment directly to the lungs.
GLA.

I’m going with RM’s comments (share holder meeting pre-Covid) sometime ago now, a company that has successfully completed a Phase3 trial could achieve a 4-6 billion valuation.

I know his audience was Synairgen shareholders however, I believe if our results mimic Phase2 it is possible and maybe even more.

Condolences Mact4 to you and your friends family.
Let’s hope that SGN can make a difference for the future.

Really heart warming to see fellow investors in Synairgen banding together to help/advise (Mact4).

Here’s hoping Mact4 you are successful in your quest.

Josh, as far as I’m aware Synairgen successfully applied for IND status in the USA, that’s why I believe the woman who was treated there was able to gain access to SGN001 through the doctor treating her.

As far as I’m aware the MAP/Clin agreement will assist in distribution once an EUA is obtained.